原发性肝细胞癌的免疫标志物  

Immunomarkers of Primary Hepatocellular Carcinoma

作　　者：刘小梅[1] 蔡茹艺 信钰 张红凯 LIU Xiaomei;CAI Ruyi;XIN Yu;ZHANG Hongkai(Department of Pathology,Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China)

机构地区：[1]首都医科大学北京中医医院病理科,北京100010

出　　处：《标记免疫分析与临床》2023年第7期1243-1249,共7页Labeled Immunoassays and Clinical Medicine

摘　　要：原发性肝细胞癌是威胁人类生命健康的常见恶性肿瘤之一。肝细胞在长期诱癌因素的诱导下发生一系列改变,由肝细胞再生结节、低级别异型增生结节、高级别异型增生结节、早期肝细胞癌到进展期肝细胞癌。患者的预后及生存质量随着这一系列病变的发生、发展逐渐降低。因此,肝细胞癌的早期诊断显得尤为重要。但是由于这些病变的形态多样,具有一定的重叠,仅仅依靠形态学有时很难进行鉴别与诊断。临床工作中,有选择性的联合应用多种免疫标志物,可以有效提高肝细胞癌的检出率。本文将对Glypican-3、HepPar-1、AFP、CD34、Arg-1、CENPF、IMP-2和HSP 60等免疫标志物进行阐述,便于临床工作者选择性的进行组合,寻找个体化的组化Pannel。肝细胞癌术后复发率高是困扰医学界的难题之一。本文介绍了目前热门的相关免疫标志物,如SLeX、SUZ12、HP1BP3、CCR1、DCP。临床检测这些免疫标志物的表达情况,可以预测患者的预后情况,针对性的选择辅助治疗方法,提高患者的无瘤生存时间及生活质量。Hepatocellular carcinoma is the most common histological type of primary HCC.Under the influence of chronic inflammation and liver cirrhosis,hepatocytes constantly change and regenerate.Inspired by long-term cancer-mutagenic factors,hepatocytes undergo a series of alterations,ranging from hepatocyte regenerative nodules,low-grade dysplasia nodules,high-grade dysplasia nodules,and early hepatocellular carcinoma to advanced hepatocellular carcinoma.The patient prognosis and quality of life gradually decrease with the occurrence and development of this series of lesions.Therefore,the early diagnosis of HCC is particularly important.Due to the diverse morphology of these lesions,it is difficult for clinicians to differentiate and diagnose them by relying on morphology alone.In clinical practice,selective combined application of multiple immunomarkers can effectively improve the detection rate of hepatocellular carcinoma.In this paper,immunomarkers,such as Glypican-3,HepPar-1,AFP,CD34,Arg-1,CENPF,IMP-2 and HSP 60,are introduced,so as to facilitate the selective combination and search for individualized immunomarkers panels.The high recurrence rate of hepatocellular carcinoma post-operation is one of the difficult problems world-wide.In this paper,popular immunomarkers,such as SLeX,SUZ12,HP1BP3,CCR1 and DCP,are elaborated.The expressions of these immunomarkers can predict the prognosis of patients.Select targeted adjuvant therapy can improve the tumor-free survival time and quality of life of patients.

关 键 词：原发性肝细胞癌 早期肝细胞癌 免疫标记物 预后 

分 类 号：R735.7[医药卫生—肿瘤]